higher anti-Xa activities. Accuracy was greater in the automated systems.
We conclude that this protocol is feasible and is applicable to validation of other analytical hemostasis instruments, in particular the latest generation of fully automated instruments.
INDEXING TERMS:
anti-factor Xa #{149} hemostasis #{149} standardization
The Soci#{233}t#{233} Fran#{231}aise de Biobogie Clinique (SFBC) has published several protocols for validation of biochemical analytical systems and methods
[J].b0
An American conference "on a national understanding for the development of reference materials and methods for clinical chemistry"
[2] also yielded recommendations.
However, these protocols deal mainly with evaluation of biochemical instruments [1] . The few protocols described for coagulation testing have dealt only with clotting assays [3, 4] , prompting us to adapt the general SFBC protocol [1] to specific needs in hemostasis.The increasingavailability of automated coagulation instruments means that validationof such protocolsisnow a realpossibility. The enzyme kinetics of coagulation is similar to that observed in biochemical assays. However, in coagulation testing, preanalytical variables, such as sample preparation (i.e., avoidance of platelet protein release), may affect protocol instructions.
Low-molecular-weight heparins (LMWH) are increasingly common in clinical practice. They barely affectthe activated partial thromboplastin time (APTT) because their anti-ha activity is much less than their anti-Xa activity. Unlike unfractionated heparin (UFH), which can be monitored by APTT and (or) heparin activity [anti-Ila and (or) anti-Xa], LMWH therapy can be monitored only by measuring anti-Xa activity [5] . Laboratory automation has been applied to this measurement to Behring dhromotmmer Bermchrom heparmn dommercial H#{244}pital de Douai improve analytical performances [6] . We therefore thought it of interest to adapt the SFBC protocol to evaluation of analytical systems that measure anti-Xa activity by chromogenic assays with synthetic substrates or by clotting assays, which are less specific [7] [8] [9] [10] . The SFBC recommended a method for measuring the anti-Xa activity of UFH [11] . This method was validated with LMWH [12] . The chromogenic method used is based on inhibition of factor Xa by the LMWH-antithrombin III (AT III) complex, with subsequent colorimetric measurement of residual factor Xa [13, 14/. In this study, our aim was to define a simple protocol suitable for systems analyzinghemostasis and to validateit in a multicenter study, using anti-Xa activity of LMWH measurement as an example.
Matenals and Methods
Protocol steps. As recommended in the SFBC protocol [1] , the evaluation consisted of three steps.First, a period of familiarization over 3 consecutive days allowed technologists to become acquainted with instrument handling and setup (e.g., room temperature, power supply, humidity) and to determine withinrun precision.
Second, in a preliminary 2-day period, the analytical range (linearity and detection limits) and the effect or carryover between samples or reagents [15, 16] were studied. During these first two periods, day-to-day precision (reproducibility and accuracy) was assessed in controls to detect any anomaly before more comprehensive studies.
Step 3 was the validationperiod (atbeast3 weeks), in which we assessedthe accuracy of the assays on patients' plasmas, comparing the results obtained with those of a validated method [12] [13] [14] . Precision (reproducibility of the calibration curves, day-to-day precision) was also evaluated during this period. Two expert laboratories performed the validated ("reference") method to determine thatthe requiredcriteria had been met. We then analyzed data as recommended in the general SFBC protocol.
The limits of acceptability of statistical criteria had already been set according to our experience of routine LMWH monitoring.
Analytical systems and reagents. An analytical system comprises the instrument, the appropriate reagents, and the method. The kinetic analyzers evaluated in the described protocol were those routinely used in the participating laboratories ( [19] . The "reference"method was performed with the SB 300, which had been used in a previous French collaborative study [12] , and with the ST 888. Evaluationmethods.Within-run precision was determined over 3 consecutive days by replicating (n = 20) the anti-Xa assay of the three byophibized controls. We assessed the reproducibility of the calibration curves at beast 18 times with the byophibized Caliplasma HBPM plasmas for each series of anti-Xa determination. We assayed the control samples at the beginning and end of each series (18 days) to assess day-to-day precision of the systems. We subjected each of the three byophilized within-run precision control plasmas to 36 anti-Xa assays. The upper limits of the SD had already been fixed at 0.02, 0.04, and 0.06 kIU/L for the three activity concentrations of 0.2, 0.4, and 0.8 kIU/L, respectively (corresponding to CVs of 10%, 10%, and 7.5%), according to clinical interpretation. We assessed linearity by adding the IS for LMWFI to the "zero" plasma to yield anti-Xa activity of 1.30 kIU/L. This was further diluted in the zero plasma to obtain additional activity concentrations, according to the protocol instructions. We assayed each of the 14 diluted samples in triplicate during the 2 days of the preliminary period. We determined the limitof detection(representedby 3 SD from the mean absorbance)with 20 replications of the anti-Xa assays of the zero plasma.
To assess carryover, we analyzed on 2 consecutive days the samples prepared at bow (L) and high (H) concentrations, according to the sequence H1 H2 L1 L2 H1 H2 L1 L2 H1 H2.L1 L2 H1 H2 L1 L2 H2 H2 L1 L2 H1 H2 L1 L2. We then calculated any differences between the absorbances of samples L1 (possibly contaminated) and L2.
We tested analyticalaccuracy by comparing the systems' results over 4 days for treated patients' samples. Each participating laboratory assayed each plasma twice; in case of discrepancy between duplicate data or with reference data, the laboratory concerned received another aliquot.According to the criteria for reproducibility, a discrepancy was defined as a difference >20% of the lower duplicate value or a difference >20% of the reference value.
Statistical analysis. We assessedthe precisionof the mean, SD, and CV with statistical Statview software and compared the mean absorbances of L1 and L2 samples from the carryover study by Student's t-test. If the differences were significant, we calculatedthe contaminant effectIc with the formula: Ic % (L1 -L,)/(fl2 -L2) x 100. We determined linearityby plotting the measured activities against the theoretical activities.
For each analytical system, we also used another representation, expressing the ratio (measured value/theoretical value) X 100 as a function of the theoretical activities for each heparin concentration. Relationships between data sets were evaluated by linear regression analysis (Deming). The differences between the tested (y)and comparison (x) methods were also plotted against the comparison methods' values [22] . Limits of acceptance were ±15% of the comparison method value, according to clinical interpretation.
Correlation between systems was also assessed by one-way ANOVA with repeated measures.
Results
Precision. For within-run precision, anti-Xa assays for the three heparin concentrations ( Table 2) showed dispersions of 2-10% for the automated instruments A and B, 4-15% for system C, and 12-27% for semiautomated system D. Dispersion was greateratlow concentrations. Mean activity was similarin three systems and slightly higher in system D. Day-to-day imprecision (Table 3) was generallygreater with semiautomated systems (CVs 5-23% vs 3-17% for the automated systems), although similarresultswere obtained with automated system A and Table 1 . semiautomated system C. Means were similar to those obtained in the precision study.
The reproducibility study with calibration curves (Table 4 ) revealedsimilardispersions in absorbancesfor systems A, B, and Analyticalrange. As Fig. I shows, for all four systems, the regression line deviates slightly from the line of identity for anti-Xa values exceeding -1.00 kIU/L. This is more obvious when the percentage deviation from theoretical values is represented for each heparin concentration.
Greater dispersion was noted with the semiautomated instruments, regardless of the amount of anti-Xa activity. In contrast, automated instruments showed only variations at bow and high concentrations of heparin. The detection threshold for anti-Xa was <0.05 kJUIL for allfour systems.
Canyover. We found no contaminant carryovereffect, as shown by the lack of significant difference by Student's t-test between the absorbances of the potentially contaminated and the noncontaminated samples (seeMaterials and Methods). Accuracy. We chose system A as the reference for the three other analytical systems (Fig. 2a, b , c) and system C as the reference for the semiautomated instruments only (Fig. 2d) . The range of acceptable measurement was set as the interval between the limit of linearity and the limitof detection(1.00 and 0.05 kIU/L, respectively) and was used to evaluate statistically the results for 85 treated patients' plasmas.
The slopesof the regressionlineswere closeto unity for the four systems (r = 0.936-0.967) (Fig. 2 ). Despite these acceptable data, we observed negative intercepts, mainly with the semiautomated instruments. Worthy of note were the bower and more scattered results given by the semiautomated systems, especially system D (Fig. 2) At high anti-Xa activity (0.80-1.0 kIU/L), therewas no significant difference in results among the four systems.
Discussion
A simplified protocol,derived from the generalSFBC protocol and specially definedtovalidate analytical systems of hemostasis, was validatedby a multicenterstudy of chromogenic measurements of anti-Xa activity in LMWH, the variablechosen as an example.
Although clinical trials have noted that LMWH monitoring is unnecessary [23, 24J , it still may be clinically useful in some clinical cases,i.e., renal insufficiency, obesity, bleeding diathesis, or risk of over-or underdosing [25, 26] . The Reference Method for this variable, as proposed by the French Hemostasis Committee [11] , has been adapted to automated and semiautomated systems.One would expectthe same reagentsto be used with the four instruments evaluated, but the best performances should be obtained with the use of appropriate reagents foreach instrument.
This ledus to compare the various part of the systems,includingthe instrument, the reagent,and the adaptation.
In this preliminary study we dealtwith very few systems and centers,so that the feasibility, practicability, and simplicity of the proposed protocol could be evaluated. As stipulated in this protocol, the limits of acceptability of different statistical criteria must be clearlyfIxed beforehand. Interpretationof results depends on whether LMVVH is used prophylactically (range of LMWH activities: 0.2-0.4 kTU/L) or therapeutically (range: 0.5-1.0 kIU/L). We therefore chose the limits of acceptability in bightof the clinical context,ratherthan the laboratorycriteria for spectrophotometric methods. ATe used byophilizedplasmas at three anti-Xa activities to determine within-and between-assay precision.
Regardless of the amount of heparin activity, the mean valuesrecorded over the two first periods with each system were similar to the target values for each control sample. Data dispersion with repeated measurements on the automated instruments were within the limits of acceptability of the protocol,which had been assigned according to the clinical interpretation [5, 27] . Greatest dispersionswere noted at low anti-Xa activity, especially for semiautomated instruments. Similarly, the semiautomated instruments gave slightly higher mean values than did the automated systems, especially for samples with low anti-Xa activities. This observation is especially relevant for system D at any anti-Xa concentration and must be considered when using semiautomated instruments to monitor prophylactic treatment with LMWH [28] . Day-to-day precision was greater than within-run precision, whatever the anti-Xa activities. Only system B was in agreement with the limitsassignedby the protocol,despitethe predilution of sample requiredwith thissystem.Even ifpoor precisionisof little consequence for prophylaxis, performances observed with systems A, C, and D at high anti-Xa concentrations may have practicalimplicationsin monitoring therapy with LMWH. Furthermore, the large between-assay variations of calibration curves (see Table 4 ) with semiautomated instruments suggest the necessity of plottinga calibration curve before each series of assays. For the automated instruments, the calibration check is highly dependent on instrument performance. Absence of carryover from sample to sample and a low detectionthreshold(<0.05 kIU/L) were appreciablecharacteristics of allfour systems. The upper limitof the analytical range was -1.00 kIUIL (maximum).
The scatter of values around the identity line was greaterfor the two semiautomated systems (Fig.1, C and D) than for the automated ones. This upper limitof linearity is important to consider clinically for monitoring LMVVH therapy,given thatheparin concentrations-1.50 kIU/L arenot rare [5] . Laboratory technologists should be aware of this problem, because the highlyheparinizedpatients' samples must be diluted in a nonheparinized plasma so that the result will lie in the linear partof the calibration curve and equilibriumof the heparin-AT III complex will be adequate.
The current tendency of some manufacturers to provide calibration plasmas titrating to 1.30 kIU/L (e.g., Cabiplasma), without a recommendation forsample dilution, is questionable.
Considering only the regression lines between the four systems, we found acceptable accuracy when comparing anti-Xa measurements for patients' frozen plasma samples. Careful analysis of the differential plots and ANOVA confirmed the similarity of data collected with the two automated instruments (Fig. 1A) , although 15% of the values were outliers with respect to the protocol-defined limits. Semiautomated instruments, especially system D, gave systematically bower and more scattered results (27-37% were outliers) for all activities <0.60 kIU/L. Thus, the data scatter noted in the study of lyophilized samples was also seen with frozen samples.
With system D, anti-Xa activities measured in high-activity byophilized samples were overestimated in comparison with the targetvalue,whereas those from frozensamples were lower than with other systems. The fact that the byophilized plasmas, which had a higher absorbance than the frozen plasmas tested, were used for calibration suggests a problem of interference from plasma turbidity in system D, as reported in spectrophotometric assays [29] . Thus, fresh, or at least deep-frozen, samples should be used whenever possible to evaluate protocols applied to coagulation. Lyophibized plasmas are also more likely to give more broadly dispersed values than non-deep-frozen ones [30] . The origin of the calibrating specimens and (or) the controls is therefore worth considering in any protocol [31] . This study tested analytical systems by assessing the instrument, the reagents,and the method adaptation.Theoretically, the protocol was evaluated under the best conditions (routinely used instrument and reagents, technician familiar with the instrument), which had been checked before the study. Compared with results of previous reports [12, 18, 19] , the magnitude of dispersion found with the semiautomated instruments for anti-Xa measurement may be surprising. In fact, semiautomated instruments require the presence of a technicianand rigorous respect of the method. The kinetics of enzymatic reactions in coagulation involving chromogenic substrates are sensitive to variations in such assay conditions as temperature (37 #{176}C) and (short) incubation times, which are difficult to ensure manually.The choiceof reagents(fora one-or two-stage assay), and then their adaptation to the instrument, could affect the reliability of the results. In conclusion,we adapted a general biochemical protocolto a coagulationvariablethatisawkward to measure, given that it involves a two-stage assay. The protocol proved feasible, simple, and practicable. Indeed, the instruments testedwere alreadywell known and routinelyused. Our study confirmed that automated instruments were more accurate than semiautomated instruments, at least for some chromogenic assays.Moreover, applicationof this protocol revealed that allfour of the instruments failed to meet some criteria, in particular criteria of accuracy according to clinical interpretation.
Results of the protocol also emphasized the need for full automation in measurement of anti-Xa activityof heparin. Investigation of carryover between assays involving contaminant reagents (e.g., thrombin), ease of handling of the analytical system, acceptability of different reagents, "open" ("random") access, expression of the results, computerization, and ergonomy is also mandatory in the general protocol. This validation of the study protocol means that it may be applied to chromogenic assays performed with the new generation of fully automated instruments currently being released onto the market. It would be of interest to evaluate the application of this protocol to clot-based assays [32] .
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